Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation.

Taramasso, Maurizio; Benfari, Giovanni; van der Bijl, Pieter; Alessandrini, Hannes; Attinger-Toller, Adrian; Biasco, Luigi; Lurz, Philipp; Braun, Daniel; Brochet, Eric; Connelly, Kim A; de Bruijn, Sabine; Denti, Paolo; Deuschl, Florian; Estevez-Loureiro, Rodrigo; Fam, Neil; Frerker, Christian; Gavazzoni, Mara; Hausleiter, Jörg; Ho, Edwin; Juliard, Jean-Michel; ... (2019). Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. Journal of the American College of Cardiology, 74(24), pp. 2998-3008. Elsevier 10.1016/j.jacc.2019.09.028

[img] Text
Transcatheter Versus Medical Treatment of Patients with symptomatic severe Tricuspid Regurgitation.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (645kB) | Request a copy


Tricuspid regurgitation is associated with increased rates of heart failure (HF) and mortality. Transcatheter tricuspid valve interventions (TTVI) are promising, but the clinical benefit is unknown.


The purpose of this study was to investigate the potential benefit of TTVI over medical therapy in a propensity score matched population.


The TriValve (Transcatheter Tricuspid Valve Therapies) registry collected 472 patients from 22 European and North American centers who underwent TTVI from 2016 to 2018. A control cohort formed by 2 large retrospective registries enrolling medically managed patients with ≥ moderate tricuspid regurgitation in Europe and North America (n = 1,179) were propensity score 1:1 matched (distance ± 0.2 SD) using age, EuroSCORE II, and systolic pulmonary artery pressure. Survival was tested with Cox regression analysis. Primary endpoint was 1-year mortality or HF rehospitalization or the composite.


After matching, 268 adequately matched pairs of patients were identified. Compared with control subjects, TTVI patients had lower 1-year mortality (23 ± 3% vs. 36 ± 3%; p = 0.001), rehospitalization (26 ± 3% vs. 47 ± 3%; p < 0.0001), and composite endpoint (32 ± 4% vs. 49 ± 3%; p = 0.0003). TTVI was associated with greater survival and freedom from HF rehospitalization (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.46 to 0.79; p = 0.003 unadjusted), which remained significant after adjusting for sex, New York Heart Association functional class, right ventricular dysfunction, and atrial fibrillation (HR: 0.39; 95% CI: 0.26 to 0.59; p < 0.0001) and after further adjustment for mitral regurgitation and pacemaker/defibrillator (HR: 0.35; 95% CI: 0.23 to 0.54; p < 0.0001).


In this propensity-matched case-control study, TTVI is associated with greater survival and reduced HF rehospitalization compared with medical therapy alone. Randomized trials should be performed to confirm these results.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan, Wild, Mirjam Gauri


600 Technology > 610 Medicine & health








Nadia Biscozzo

Date Deposited:

10 Feb 2020 13:24

Last Modified:

02 Mar 2023 23:33

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

heart valve diseases tricuspid regurgitation tricuspid valve




Actions (login required)

Edit item Edit item
Provide Feedback